Memo Therapeutics
About:
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.
Website: https://memo-therapeutics.com
Top Investors: Verve Ventures, Fresenius Medical Care, Zürcher Kantonal Bank, Schroders Capital, redalpine
Description:
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
$109M
$1M to $10M
Schlieren, Zurich, Switzerland
2012-01-01
info(AT)memo-therapeutics.com
Christoph Esslinger
11-50
2024-05-07
Private
© 2025 bioDAO.ai